Get our lovely INSIGHT 2019 conference news

Email address
First Name
Last Name
Interested in InSight 2019

What are you looking for?

<Good_things_happen/> Welcome to Conference

Direct within-subject comparison of the acute subjective and autonomic effects of LSD, MDMA, and amphetamine in healthy subjects

Oral Presentation

Acute effects of a prototypic hallucinogen, entactogen, and stimulant have never been compared directly within healthy subjects. Therefore, we assessed and compared responses to the hallucinogen lysergic acid diethylamide (LSD), the entactogen 3,4-methylenedioxymethamphetamine (MDMA), the stimulant d-amphetamine, and placebo in humans in a controlled laboratory setting.
We used a double-blind, placebo-controlled, cross-over study design in 28 healthy volunteers (14 females, 14 males) to investigate the acute subjective and autonomic responses to 0.1 mg LSD, 125 mg MDMA, 40 mg d-amphetamine, and placebo. Acute subjective drug effects were assessed using visual analog scales (VASs), the adjective mood rating scale (AMRS), the addiction research inventory (ARCI), and the five-dimensions of altered states of consciousness scale (5D-ASC). Mystical experiences were assessed with the 30-item Mystical Experience Questionnaire (MEQ30). Maximal responses were compared using repeated-measures ANOVAs followed by Tukey post-hoc tests.
All substances significantly increased blood pressure, heart rate, and body temperature compared with placebo (all p<0.001). d-Amphetamine showed a significantly larger increase in blood pressure compared with LSD and MDMA (both p<0.001). All substances produced a significant increase in VAS good drug effect, drug liking, drug high, happiness, and trust ratings (all p<0.001). On the AMRS, MDMA and d-amphetamine both increased concentration (p<0.01 and p<0.001, respectively), self-confidence (both p<0.01), heightened mood (both p<0.01), and well-being (both p<0.001). Only LSD increased bad drug effect (p<0.001), fear (p<0.001), speed of thinking (p<0.01), and change in the sense of time (p<0.001) in the VASs. Additionally, only LSD significantly increased ratings of anxiety in the AMRS (p<0.001). LSD produced significant effects on all subscales of the ARCI whereas d-amphetamine and MDMA only showed effects on the Amphetamine and Morphine-Benzedrine Group scales (all p<0.001). LSD significantly increased effects on all 5D-ASC dimensions and subscales, whereas MDMA only increased “blissful state” ratings (p<0.01). MDMA and LSD increased ego dissolution (“the boundaries between myself and my surroundings seemed to blur”) (p<0.01 and p<0.001, respectively) on the 5D-ASC. Furthermore, LSD significantly increased all MEQ30 scores compared with placebo. MDMA increased ineffability (p<0.001), positive mood (p<0.001), and transcendence (p<0.05) on the MEQ30. In contrast, d-amphetamine produced no alterations of mind on the 5D-ASC and no mystical-type experiences in the MEQ30.
LSD, MDMA, and d-amphetamine produce separable acute subjective responses in healthy humans. In particular, LSD induced subjective effects that were clearly very distinct from those of MDMA and d-Amphetamine.



September 6th 2019


16:30 - 17:00


Friederike Holze

Friederike Holze

Clinical Pharmacology and Toxicology, University Hospital Basel more about the speaker

Related Events

Psilocybin-Assisted Treatment of Alcohol Use Disorder: Historical Context and Current Clinical Research

The use of classic psychedelics in the treatment of alcohol use disorder dates to Hoffer and Osmond’s work with LSD in Saskatchewan starting in 1953. Initially seen as a way to safely induce a delirium tremens-like experience, LSD was tested in clinical trials and used in treatment programs for thousands of patients through the early 1970s, resulting in substantial but inconclusive evidence for its effectiveness. With increasing restriction of access to psychedelics for reach purposes, LSD research ceased in the […]

more details

The ketamine breakthrough: a new paradigm for the treatment of depression and pain

The ketamine breakthrough: a new paradigm in the treatment of depression and pain Tharcila Chaves University of Groningen, The Netherlands The proposed presentation aims to acknowledge the cutting-edge and avant-garde properties of ketamine as a tool to treat persistent physical and mental pains. The rapid antidepressant effect of the well-known anaesthetic drug ketamine in patients with treatment-resistant depression (TRD) is considered the most important advance in the pharmacotherapy of depression in 50 years. Depression has surpassed HIV/AIDS, malaria, diabetes and […]

more details

The notion of “experience” – and it’s importance for psychedelic integration work

What does ‘having an experience’ mean? Why does it matter to think about that, when we are talking about the integration of psychedelic experiences? In a very broad sense, everything is ‘experience’. But because that empiricist notion means a lot, it maybe doesn’t say too much. In a more tangible way, ‘having an experience’ refers to distinct processes, sometimes leading to quite dramatic real life implications for a specific human being. An experience as a whole always reveals something – […]

more details

Conference tickets

With your ticket you will have access to the whole conference - with keynotes, panels, round tables, posters and daylight social events. We will ask for a small extra fee for the Friday evening social program. The pre-conference workshops have to be booked separately and each workshop needs an individual ticket. By clicking on "Book now" below you also have the option to buy your workshop tickets.

*Reduced fees apply to students, cooperation partners as well as unemployed and retired individuals who have a monthly net income below 840,- €. Proof of status will be required.

THE CONFERENCE IS SOLD OUT! Subscribe to our newsletter to become an early bird for 2021!

Get our lovely INSIGHT 2019 conference news

Email address
First Name
Last Name